Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
テクノロジー·イーライ・リリー

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
テクノロジー·イーライ・リリー

Eli Lilly licenses Peptron’s SmartDepot by October 7?

45% 確率
Polymarket
新規
45% 確率
Polymarket
新規
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic pivot toward oral GLP-1 agonists such as orforglipron, combined with its June 2025 licensing of Camurus’ FluidCrystal long-acting injectable platform, has tilted trader sentiment against a near-term commercial license for Peptron’s SmartDepot sustained-release microsphere technology. The original October 2024 evaluation agreement was extended in December 2025 through October 7, 2026, to allow further in-vivo studies on Lilly’s peptide candidates, yet no technology-transfer announcement has occurred despite ongoing joint research. With roughly five months remaining until the resolution date, traders view the absence of a binding commercial deal as the dominant factor supporting the current 55% implied probability on “No.”

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$8,308
終了日
2026/10/07
マーケット開始日
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic pivot toward oral GLP-1 agonists such as orforglipron, combined with its June 2025 licensing of Camurus’ FluidCrystal long-acting injectable platform, has tilted trader sentiment against a near-term commercial license for Peptron’s SmartDepot sustained-release microsphere technology. The original October 2024 evaluation agreement was extended in December 2025 through October 7, 2026, to allow further in-vivo studies on Lilly’s peptide candidates, yet no technology-transfer announcement has occurred despite ongoing joint research. With roughly five months remaining until the resolution date, traders view the absence of a binding commercial deal as the dominant factor supporting the current 55% implied probability on “No.”

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
音量
$8,308
終了日
2026/10/07
マーケット開始日
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

外部リンクに注意してください。

よくある質問

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」はPolymarket上の予測市場で、トレーダーがこのイベントが起こるかどうかに基づいて「はい」または「いいえ」のシェアを売買します。コミュニティによる現在の確率は「Yes」に対して45%です。例えば、「はい」が45¢で取引されている場合、市場はこのイベントが発生する確率を45%と集合的に評価しています。これらのオッズはトレーダーが新しい展開や情報に反応するにつれて継続的に変化します。正しい結果のシェアは市場決済時に各$1で引き換え可能です。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」はPolymarket上で新しく作成された市場です（May 6, 2026開始）。早期の市場として、最初のトレーダーの一人としてオッズを設定し、市場の初期価格シグナルを確立するチャンスです。このページをブックマークして、取引量と活動を追跡することもできます。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」で取引するには、答えが「はい」か「いいえ」かを選ぶだけです。各側には市場の暗示確率を反映する現在の価格があります。金額を入力して「取引」をクリックします。「はい」のシェアを購入し、結果が「はい」と決まった場合、各シェアは$1を支払います。「いいえ」と決まった場合、「はい」のシェアは$0を支払います。決済前にいつでもシェアを売却して利益を確定したり、損失を抑えたりすることもできます。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」の現在の確率は「Yes」に対して45%です。これはPolymarketコミュニティがこのイベントの発生確率を45%と現在評価していることを意味します。これらのオッズは実際の取引に基づいてリアルタイムで更新され、市場の期待を継続的に反映するシグナルを提供します。

「Eli Lilly licenses Peptron’s SmartDepot by October 7?」の決済ルールは、各結果が勝者と宣言されるために何が起こる必要があるかを正確に定義しています。これには結果を決定するために使用される公式データソースも含まれます。このページのコメント上にある「ルール」セクションで完全な決済基準を確認できます。取引前にルールを注意深く読むことをお勧めします。